Plain Language Summary

What is it about? The study explores the potential benefits of making semaglutide, a medication used to treat type 2 diabetes, obesity, and metabolic-associated steatohepatitis (MASH), widely available to people covered by Medicare. This research is important because these conditions often lead to worse health outcomes and higher healthcare costs. The researchers aimed to determine how access to semaglutide for all FDA-approved indications could impact health outcomes and costs for Medicare. Previously, there was limited research on the comprehensive impacts of semaglutide across overlapping health conditions. By examining these impacts, the study suggests semaglutide could provide substantial value to Medicare, providing substantial health benefits and cost savings.

How was the research conducted? The study used cohort simulation modeling to predict health outcomes and costs over 10 years, from 2026 to 2035. This approach involved analyzing data from government reports, clinical studies, and real-world claims to model the effects of semaglutide availability compared to no availability. The researchers focused on patients with diabetes, obesity, and MASH, and they estimated the number of people eligible for semaglutide treatment each year. They used data on drug prices, estimated utilization, treatment adherence, clinical effect, and healthcare costs to simulate outcomes. Of note, the drug prices used for semaglutide were based on estimates of the Medicare negotiated price planned to go into effect in 2026. The researchers chose this method because it allows for a comprehensive analysis of long-term health and economic impacts.

What were the results? The main finding is that providing Medicare patients access to semaglutide could prevent approximately 38,950 cardiovascular events and 6,180 deaths over 10 years. Additionally, it could save Medicare between $412 million and $1.71 billion, depending on different scenarios, such as changes in utilization or price due to future generic versions. The study also found benefits of semaglutide in reducing costs associated with sleep apnea, knee replacements, chronic kidney disease progression, and MASH progression.

Why are the results important? These results have significant real-world implications, suggesting that broad access to semaglutide could lead to better health outcomes and reduced healthcare costs for Medicare. In practical terms, this could mean fewer hospitalizations and improved quality of life for patients with diabetes and obesity. The findings are particularly beneficial for policy makers considering patient access to semaglutide, as well as for Medicare beneficiaries who could experience improved health and reduced out-of-pocket expenses. Long-term, the results could impact future healthcare policies, encouraging broader coverage of effective medications like semaglutide to improve public health and reduce costs.

What are the strengths and weaknesses of this study? A key strength of this study is its comprehensive approach, using diverse data sources to model long-term outcomes and economic impacts. However, a limitation is the uncertainty in predicting future drug utilization and prices, which could affect the accuracy of cost savings estimates. Future research could focus on real-world data to refine these predictions and explore the impacts of semaglutide on other health outcomes not covered in this study.

^{Note: This content was created with assistance from artificial intelligence (AI) and has been reviewed and edited by ISPOR staff. For more information or for inquiries on ISPOR’s AI policy, click here or contact us at info@ispor.org.}